All News
PIANO Study - Safety of Biologics in Pregnancy
The results of the long awaited PIANO study have been reported in the journal Gastroenterology, showing that pregnant women with IBD may safely receive biologic or thiopurine therapy throughout the pregnancy without substantial added risk to the unborn or mother.
Read Article
Racial disparities in Bilateral Knee Arthroplasty in Osteoarthritis
Although arthritis-related activity, disabling work limitations, and severe pain (which are indications for TKA) disproportionately impact African American patients compared to White patients, there are marked racial disparities documented in utilization and complications in unilateral total knee arthroplasty.
Read Article
Rheumatology Round-Up with Drs. Kavanaugh & Cush
The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020. Watch now!
Read Article
Systemic Sclerosis and Physical Therapy
Systemic sclerosis (SSc) is a chronic fibrosing disease currently with no available cure.
Read Article
ACR20 - Day 2 Report
Saturday was the day 2 with many posters and live sessions at the 2020 Virtual ACR/ARP meeting. Here are a few of my highlights from day two:
Read Article
ACR Best Abstracts - Day 1
The RheumNow faculty reporters have been glued to their monitors all day, viewing video, reading and listening to abstract presentations and I charged them to earmark those presentations were the “Best” they saw today. Below is the list of most often noted #ACRbest abstracts from Day 1.
Read Article
Industry Abstract Previews - ACR2020
Each pharmaceutical company has spent months and years preparing to present and highlight their featured clinical trials and abstracts at ACR 2020. This is our selection of their best studies for you to review and evaluate as part of your to-do list.
Read Article
TNF Inhibitor Associated Infectious Risk Greatest in First 6 Months
The risk of serious infections (SIE) in RA patients given anti-TNF (TNFi) therapy is not static, instead it has been shown to be greatest in the first 6 months of use according to a recent report in Rheumatology.
Read Article
Long-Term Benefits of Ixekizumab in Psoriatic Arthritis
The SPIRIT-P1 study has demonstrated the safety and efficacy of ixekizumab (an IL-17A antagonist) when given to adults w/ active psoriatic arthritis (PsA), and also demonstrating radiographic protection and improvement in skin outcomes as well.
Read Article
SPARTAN ACR20 Recommendations on Spondyloarthritis
SPARTAN has compiled a list of presentations and sessions worth seeing if you are interested in ankylosing spondylitis, spondyloarthritis and related disorders.
Read Article
RheumNow Podcast – ACR 20 is Coming to Town (10.30.20)
Dr Jack Cush overviews the RheumNow commitment, upcoming bonus coverage of ACR20 and the good news and journal reports from the past week on RheumNow.com
Read Article
FDA Invites Patient Input on Systemic Sclerosis Drug Development
While there have been several promising new agents for systemic sclerosis, many have failed - with all noting the difficulties in appropriate outcomes and endpoints for clinical trials. With this in mind, the FDA was interested in hearing patients’ perspectives on systemic sclerosis and new drug development, and held a virtual meeting on 10/13/20.
Read Article
Guselkumab, an IL-23 Inhibitor, Effective in Psoriatic Arthritis
The DISCOVER‐2 trial has shown that guselkumab, an interleukin‐23p19 was shown to be safe and effective in biologic‐naïve psoriatic arthritis (PsA) patients in a one year study.
Read Article
Fibromyalgia Therapies Show Limited Evidence of Pain and QOL Reduction
JAMA Internal Medicine has published a review showing that most currently approved therapies for fibromyalgia (FM) do not have high-quality evidence to support their use; with some reducing pain or improving quality of life (QOL) in the short term, but overall effect size is not impressive.
Read Article
Vedolizumab Promising in Immune-Related GI Events
Vedolizumab (Entyvio) was superior to infliximab (Remicade) for treating immune-mediated diarrhea and colitis (IMDC), a researcher reported.
Read Article
Immune Necrotizing Myopathy
A full read review of immune-mediated necrotizing myopathy is portrayed as a distinct subtype of inflammatory myopathies first described in 2004.
Read Article
Links:
Links:
